Covishield 63% effective overall, 81% against severe illness: Study
SECTIONS
Share
Synopsis
Despite Delta’s ability to reduce humoral/antibody-led immune response, the cell-mediated immunity - immunity driven by T cells at sites of infection - was still well preserved and could add to vaccine effectiveness, the study conducted by leading Indian researchers from top scientific institutions showed.
ET Bureau
Covishield has shown 63% vaccine efficacy overall and 81% in preventing severe Covid-19 infections in fully vaccinated people, according to the first such Indian study on its efficacy amid the virulent Delta-led second wave.
Despite Delta’s ability to reduce humoral/antibody-led immune response, the cell-mediated immunity - immunity driven by T cells at sites of infection - was still well preserved and could add to vaccine effectiveness, the study conducted by leading Indian researchers from top scientific institutions showed.
Oslo (Norway), 31 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has informed the company that a new US patent will be granted early June 2021. The US patent covers the use of fimaVacc in combination with immune checkpoint inhibitors (ICIs). The use of ICIs has revolutionised cancer immunotherapy, as this class of drugs may induce long-lasting effects in those patients responding to treatment. Unfortunately, most patients do not respond to ICI therapy and different treatment combination strategies are explored with the aim to increase the number of patients responding. Combining ICIs with therapeutic cancer vaccines that induce relevant immune responses against the tumour cells is regarded as one of the most promising strategies. The patent that soon will be granted in the US covers the use of PCI Biotech’s fimaVacc vaccination technology in combination with important classe
This figure presents serum binding and functional antibody responses following COVID-19 vaccination and SARS-CoV-2 infection among women 45 years or younger.
A and B, Each panel compares vaccine antibody responses at 2 through 8 weeks after the second dose to nonpregnant and pregnant women who were unvaccinated and infected. Thirteen women (7 nonpregnant, 4 pregnant, and 2 lactating) who had baseline samples collected within 7 days of their first vaccine dose were selected based on the earliest sample availability and were analyzed as a negative assay control.
C, D, and E, Systems serology was used to quantify spike-specific antibody–dependent neutrophil phagocytosis (ADNP), antibody–dependent complement deposition (ADCD), and antibody–dependent monocyte cellular phagocytosis (ADCP).
Forward-Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than. | February 18, 2021